Value Plus

Arihant's Value Plus - April 2019



Markets have shown some signs of positivity led by positive global cues as well as reduction in border tensions across India- Pakistan & optimism over U.S.-China trade talks. Domestically, macros have improved in terms of lower inflation, possibility of further cut in interest rates by RBI, as well as expectations of healthy growth in profits for FY20.  Among the sectors one can focus on banks, IT services & cement.

In this issue:

  • Movers and Shakers
  • Market Outlook
  • Nifty Technical Outlook
  • Stock Pick
  • Auto Sales
  • Commodity Pick
  • Mutual Fund
  • Key Events

On the monthly chart, after three consecutive narrow range body formations prices have formed strong bull candle above the median line of the channel which clearly suggests that the undertone is positive. In coming month if Nifty trades and close above 11779 level then it is likely to test 12016 – 12254 - 12530 levels. However, if Nifty trades and close below 11468 level then it can 11231 – 10994 – 10718 levels. 

Broadly, we are of the opinion that 11231 - 10994 is crucial support zone for current month as long as Nifty holds the above mentioned zone there is high probability that Nifty would test 12016 – 12254 – 12530 levels on the upside. Hence cautiously positive approach at current level should be adopted as stock specific activity is likely to continue.


Tags: Auto SalesKey EventsMutual FundNifty TechnicalMovers & ShakersMarket OutlookStock PicksCommodity Pick


Arihant's April Investment Newsletter is now available #ValuePlus.
Click here to download full pdf report.

Search Reports

SEARCH

Reports

Daily Market Update...

Nifty opened higher traded...

Read More

Daily Market Update...

Nifty opened higher but were...

Read More

Daily Market Update...

On the daily chart, we are...

Read More

Daily Market Update...

Nifty opened higher initially...

Read More

Daily Market Update...

Nifty opened on a subdued...

Read More

Greaves Cotton Q1FY20...

Greaves Cotton came out with...

Read More

Manappuram Finance Ltd...

Manappuram Finance (MFL)...

Read More

Aurobindo Pharma Q1FY20...

The company is confident of...

Read More

City Union Bank Ltd...

City Union Bank (CUB)...

Read More

Ramco Cements Ltd Q1FY20...

Ramco Cements came out with...

Read More

Subscribe to newsletter

Request a call back

DISCLAIMER: This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions.